Loading…

Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections

Liposomes have been used as targeting carriers for drug delivery systems (DDSs), and the carriers are able to be modified with targeting ligands, such as antibodies and peptides. To evaluate the targetability of DDS carriers modified with a targeting ligand, culture cells expressing the targeting mo...

Full description

Saved in:
Bibliographic Details
Published in:Biological and Pharmaceutical Bulletin 2018-07, Vol.41 (7), p.1107-1111
Main Authors: Yoichi Negishia, Nobuhito Hamanoa, Hinako Satoa, Fumihiko Katagirib, Kyohei Takatoria, Yoko Endo-Takahashia, Yamato Kikkawab, Motoyoshi Nomizub
Format: Article
Language:Japanese
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1111
container_issue 7
container_start_page 1107
container_title Biological and Pharmaceutical Bulletin
container_volume 41
creator Yoichi Negishia
Nobuhito Hamanoa
Hinako Satoa
Fumihiko Katagirib
Kyohei Takatoria
Yoko Endo-Takahashia
Yamato Kikkawab
Motoyoshi Nomizub
description Liposomes have been used as targeting carriers for drug delivery systems (DDSs), and the carriers are able to be modified with targeting ligands, such as antibodies and peptides. To evaluate the targetability of DDS carriers modified with a targeting ligand, culture cells expressing the targeting molecules as well as small animals are used. Furthermore, in vitro and in vivo screening analyses must be repeatedly performed. Therefore, it is important to establish an easy and high-precision screening system for targeting carriers. With this aim, we focused that whether this ex vivo system could easily support assessment of interaction between targeting ligand and its receptor under physiological environment and further screen the DDS carrier-modified with targeting moiety. We examined targeting ability via in vitro, ex vivo, and in vivo analyses using integrin αvβ3-targeting C16Y-L. For the in vitro analysis, the cellular uptake of C16Y-L was higher than that of control liposomes in colon26 cells. For the ex vivo analysis, we performed an immunohistochemical analysis using colon26 tumor sections. C16Y-L was specifically attached to the tumor sections, as found in the in vitro analysis. Moreover, to evaluate the ex vivo - in vivo correlation, we examined the intratumoral localization of C16Y-L. This result showed that C16Y-L was accumulated not only in the tumor tissue but also in the tumor vasculature after the intravenous injection of C16Y-L, suggesting that the ex vivo peptide-modified liposomal analysis was correlated with the in vivo analysis. Thus, the ex vivo peptide-modified liposomal analysis may be an easy and rapid screening system with high-precision and for consideration in in vivo conditions.
format article
fullrecord <record><control><sourceid>medicalonline</sourceid><recordid>TN_cdi_medicalonline_journals_cs7biolo_2018_004107_020_1107_11113111680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>cs7biolo_2018_004107_020_1107_11113111680</sourcerecordid><originalsourceid>FETCH-LOGICAL-m1359-5dd6767541c118282e992c03e09bcc79df4413678b99977e9eb88b54fcea4fd83</originalsourceid><addsrcrecordid>eNotTc1KxDAY7EHBdfUd8gKFL03bJEepugoVhXbPJU2-LFnapCRdwbd3iw4M83OYucl2IKnIa1qJu-w-pTMAcCjYLpuf8RunsMzoVxIsUaTTEdE7fyLdT1pxJjZE0qt4wnUrGxWjw5jIMW3xC5fVGcw_gnHWoSGtW0IKMyaivCG9S-mCpEO9uuDTQ3Zr1ZTw8V_32fH1pW_e8vbz8N48tflMWSXzypia17wqqaZUFKJAKQsNDEGOWnNpbFlSVnMxSik5R4mjEGNVWo2qtEawfXb4253ROK2m4CfncTiHS_TX30EnProwhaEAKgaAkgIfoICBboZewa6sBbBfkoBe7g</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections</title><source>Free Full-Text Journals in Chemistry</source><creator>Yoichi Negishia ; Nobuhito Hamanoa ; Hinako Satoa ; Fumihiko Katagirib ; Kyohei Takatoria ; Yoko Endo-Takahashia ; Yamato Kikkawab ; Motoyoshi Nomizub</creator><creatorcontrib>Yoichi Negishia ; Nobuhito Hamanoa ; Hinako Satoa ; Fumihiko Katagirib ; Kyohei Takatoria ; Yoko Endo-Takahashia ; Yamato Kikkawab ; Motoyoshi Nomizub ; aDepartment of Drug Delivery and Molecular Biopharmaceutics ; bDepartment of Clinical Biochemistry ; School of Pharmacy ; Tokyo University of Pharmacy and Life Sciences</creatorcontrib><description>Liposomes have been used as targeting carriers for drug delivery systems (DDSs), and the carriers are able to be modified with targeting ligands, such as antibodies and peptides. To evaluate the targetability of DDS carriers modified with a targeting ligand, culture cells expressing the targeting molecules as well as small animals are used. Furthermore, in vitro and in vivo screening analyses must be repeatedly performed. Therefore, it is important to establish an easy and high-precision screening system for targeting carriers. With this aim, we focused that whether this ex vivo system could easily support assessment of interaction between targeting ligand and its receptor under physiological environment and further screen the DDS carrier-modified with targeting moiety. We examined targeting ability via in vitro, ex vivo, and in vivo analyses using integrin αvβ3-targeting C16Y-L. For the in vitro analysis, the cellular uptake of C16Y-L was higher than that of control liposomes in colon26 cells. For the ex vivo analysis, we performed an immunohistochemical analysis using colon26 tumor sections. C16Y-L was specifically attached to the tumor sections, as found in the in vitro analysis. Moreover, to evaluate the ex vivo - in vivo correlation, we examined the intratumoral localization of C16Y-L. This result showed that C16Y-L was accumulated not only in the tumor tissue but also in the tumor vasculature after the intravenous injection of C16Y-L, suggesting that the ex vivo peptide-modified liposomal analysis was correlated with the in vivo analysis. Thus, the ex vivo peptide-modified liposomal analysis may be an easy and rapid screening system with high-precision and for consideration in in vivo conditions.</description><identifier>ISSN: 0918-6158</identifier><language>jpn</language><publisher>Pharmaceutical Society of Japan</publisher><ispartof>Biological and Pharmaceutical Bulletin, 2018-07, Vol.41 (7), p.1107-1111</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Yoichi Negishia</creatorcontrib><creatorcontrib>Nobuhito Hamanoa</creatorcontrib><creatorcontrib>Hinako Satoa</creatorcontrib><creatorcontrib>Fumihiko Katagirib</creatorcontrib><creatorcontrib>Kyohei Takatoria</creatorcontrib><creatorcontrib>Yoko Endo-Takahashia</creatorcontrib><creatorcontrib>Yamato Kikkawab</creatorcontrib><creatorcontrib>Motoyoshi Nomizub</creatorcontrib><creatorcontrib>aDepartment of Drug Delivery and Molecular Biopharmaceutics</creatorcontrib><creatorcontrib>bDepartment of Clinical Biochemistry</creatorcontrib><creatorcontrib>School of Pharmacy</creatorcontrib><creatorcontrib>Tokyo University of Pharmacy and Life Sciences</creatorcontrib><title>Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections</title><title>Biological and Pharmaceutical Bulletin</title><description>Liposomes have been used as targeting carriers for drug delivery systems (DDSs), and the carriers are able to be modified with targeting ligands, such as antibodies and peptides. To evaluate the targetability of DDS carriers modified with a targeting ligand, culture cells expressing the targeting molecules as well as small animals are used. Furthermore, in vitro and in vivo screening analyses must be repeatedly performed. Therefore, it is important to establish an easy and high-precision screening system for targeting carriers. With this aim, we focused that whether this ex vivo system could easily support assessment of interaction between targeting ligand and its receptor under physiological environment and further screen the DDS carrier-modified with targeting moiety. We examined targeting ability via in vitro, ex vivo, and in vivo analyses using integrin αvβ3-targeting C16Y-L. For the in vitro analysis, the cellular uptake of C16Y-L was higher than that of control liposomes in colon26 cells. For the ex vivo analysis, we performed an immunohistochemical analysis using colon26 tumor sections. C16Y-L was specifically attached to the tumor sections, as found in the in vitro analysis. Moreover, to evaluate the ex vivo - in vivo correlation, we examined the intratumoral localization of C16Y-L. This result showed that C16Y-L was accumulated not only in the tumor tissue but also in the tumor vasculature after the intravenous injection of C16Y-L, suggesting that the ex vivo peptide-modified liposomal analysis was correlated with the in vivo analysis. Thus, the ex vivo peptide-modified liposomal analysis may be an easy and rapid screening system with high-precision and for consideration in in vivo conditions.</description><issn>0918-6158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotTc1KxDAY7EHBdfUd8gKFL03bJEepugoVhXbPJU2-LFnapCRdwbd3iw4M83OYucl2IKnIa1qJu-w-pTMAcCjYLpuf8RunsMzoVxIsUaTTEdE7fyLdT1pxJjZE0qt4wnUrGxWjw5jIMW3xC5fVGcw_gnHWoSGtW0IKMyaivCG9S-mCpEO9uuDTQ3Zr1ZTw8V_32fH1pW_e8vbz8N48tflMWSXzypia17wqqaZUFKJAKQsNDEGOWnNpbFlSVnMxSik5R4mjEGNVWo2qtEawfXb4253ROK2m4CfncTiHS_TX30EnProwhaEAKgaAkgIfoICBboZewa6sBbBfkoBe7g</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Yoichi Negishia</creator><creator>Nobuhito Hamanoa</creator><creator>Hinako Satoa</creator><creator>Fumihiko Katagirib</creator><creator>Kyohei Takatoria</creator><creator>Yoko Endo-Takahashia</creator><creator>Yamato Kikkawab</creator><creator>Motoyoshi Nomizub</creator><general>Pharmaceutical Society of Japan</general><scope/></search><sort><creationdate>201807</creationdate><title>Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections</title><author>Yoichi Negishia ; Nobuhito Hamanoa ; Hinako Satoa ; Fumihiko Katagirib ; Kyohei Takatoria ; Yoko Endo-Takahashia ; Yamato Kikkawab ; Motoyoshi Nomizub</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-m1359-5dd6767541c118282e992c03e09bcc79df4413678b99977e9eb88b54fcea4fd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoichi Negishia</creatorcontrib><creatorcontrib>Nobuhito Hamanoa</creatorcontrib><creatorcontrib>Hinako Satoa</creatorcontrib><creatorcontrib>Fumihiko Katagirib</creatorcontrib><creatorcontrib>Kyohei Takatoria</creatorcontrib><creatorcontrib>Yoko Endo-Takahashia</creatorcontrib><creatorcontrib>Yamato Kikkawab</creatorcontrib><creatorcontrib>Motoyoshi Nomizub</creatorcontrib><creatorcontrib>aDepartment of Drug Delivery and Molecular Biopharmaceutics</creatorcontrib><creatorcontrib>bDepartment of Clinical Biochemistry</creatorcontrib><creatorcontrib>School of Pharmacy</creatorcontrib><creatorcontrib>Tokyo University of Pharmacy and Life Sciences</creatorcontrib><jtitle>Biological and Pharmaceutical Bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoichi Negishia</au><au>Nobuhito Hamanoa</au><au>Hinako Satoa</au><au>Fumihiko Katagirib</au><au>Kyohei Takatoria</au><au>Yoko Endo-Takahashia</au><au>Yamato Kikkawab</au><au>Motoyoshi Nomizub</au><aucorp>aDepartment of Drug Delivery and Molecular Biopharmaceutics</aucorp><aucorp>bDepartment of Clinical Biochemistry</aucorp><aucorp>School of Pharmacy</aucorp><aucorp>Tokyo University of Pharmacy and Life Sciences</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections</atitle><jtitle>Biological and Pharmaceutical Bulletin</jtitle><date>2018-07</date><risdate>2018</risdate><volume>41</volume><issue>7</issue><spage>1107</spage><epage>1111</epage><pages>1107-1111</pages><issn>0918-6158</issn><abstract>Liposomes have been used as targeting carriers for drug delivery systems (DDSs), and the carriers are able to be modified with targeting ligands, such as antibodies and peptides. To evaluate the targetability of DDS carriers modified with a targeting ligand, culture cells expressing the targeting molecules as well as small animals are used. Furthermore, in vitro and in vivo screening analyses must be repeatedly performed. Therefore, it is important to establish an easy and high-precision screening system for targeting carriers. With this aim, we focused that whether this ex vivo system could easily support assessment of interaction between targeting ligand and its receptor under physiological environment and further screen the DDS carrier-modified with targeting moiety. We examined targeting ability via in vitro, ex vivo, and in vivo analyses using integrin αvβ3-targeting C16Y-L. For the in vitro analysis, the cellular uptake of C16Y-L was higher than that of control liposomes in colon26 cells. For the ex vivo analysis, we performed an immunohistochemical analysis using colon26 tumor sections. C16Y-L was specifically attached to the tumor sections, as found in the in vitro analysis. Moreover, to evaluate the ex vivo - in vivo correlation, we examined the intratumoral localization of C16Y-L. This result showed that C16Y-L was accumulated not only in the tumor tissue but also in the tumor vasculature after the intravenous injection of C16Y-L, suggesting that the ex vivo peptide-modified liposomal analysis was correlated with the in vivo analysis. Thus, the ex vivo peptide-modified liposomal analysis may be an easy and rapid screening system with high-precision and for consideration in in vivo conditions.</abstract><pub>Pharmaceutical Society of Japan</pub><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2018-07, Vol.41 (7), p.1107-1111
issn 0918-6158
language jpn
recordid cdi_medicalonline_journals_cs7biolo_2018_004107_020_1107_11113111680
source Free Full-Text Journals in Chemistry
title Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A39%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medicalonline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20Screening%20System%20for%20Targeting%20Carriers%20Using%20Peptide-Modified%20Liposomes%20and%20Tissue%20Sections&rft.jtitle=Biological%20and%20Pharmaceutical%20Bulletin&rft.au=Yoichi%20Negishia&rft.aucorp=aDepartment%20of%20Drug%20Delivery%20and%20Molecular%20Biopharmaceutics&rft.date=2018-07&rft.volume=41&rft.issue=7&rft.spage=1107&rft.epage=1111&rft.pages=1107-1111&rft.issn=0918-6158&rft_id=info:doi/&rft_dat=%3Cmedicalonline%3Ecs7biolo_2018_004107_020_1107_11113111680%3C/medicalonline%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-m1359-5dd6767541c118282e992c03e09bcc79df4413678b99977e9eb88b54fcea4fd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true